Strategic Growth With Achillion now operating under Alexion and a clinical-stage portfolio focused on rare disease therapies, there is a clear opportunity to align sales efforts with orphan drug pathways, companion diagnostic needs, and specialized support programs to accelerate access and adoption of new treatments.

Rare Disease Focus The emphasis on oral factor D inhibitors and rare disease indications positions opportunities to engage with niche care teams, patient advocacy groups, and specialty distributors seeking optimized supply chains and patient access solutions.

Clinical Development As a mid-sized player within a larger pharma ecosystem, there is potential to propose clinical services, real-world evidence studies, and pharmacovigilance collaborations to support ongoing trials and post-market surveillance for rare disease modalities.

Strategic Partnerships Recent and potential collaborations with major industry players (AstraZeneca, Novartis, Voyager, etc.) indicate receptivity to co-development or licensing discussions; identify overlapping therapeutic areas or platform technologies for joint ventures or strategic alliances.

Data and Tech Enablement The tech stack including Qlik, Docker, DBT, MongoDB, PostgreSQL and SonarQube suggests opportunities to offer data integration, analytics, and data governance services to streamline research operations, clinical data management, and regulatory reporting.